The Proceedings of the BIRS Community


The veterinary vaccine market in Africa is forecasted to grow at a compound annual growth rate (CAGR) of 13-15%, compared to the US at 4-6% and Europe at 5-7%. In Uganda, and its neighboring countries, the livestock sector is expected to grow significantly over the next few years. BRENTEC is a young start-up company that is keen to enter this growing market. To be competitive in this market, the company has to invest in robust quality systems that enable the manufacturing of high-quality products while keeping production costs low. This has not been the case with the launch of its first product, a vaccine against Newcastle disease in poultry. The product is formulated particularly for use in climate zone IV making it superior to most imports but is priced higher than the competition because of the high production costs associated with achieving consistently high-quality product. The objective of this project is to identify the critical process steps in the manufacturing cycle that are associated with these high production costs and, using advances in the field of vaccine production to improve these processes, lower their associated costs without compromising product quality. This will allow BRENTEC to price its product affordably to improve its market access and to achieve sustainability.